

SYROS


INVESTOR FACT SHEET

Updated May 2024

OUR MISSION AND FOCUS

Syros is a biopharmaceutical company committed to developing new standards of care for the frontline treatment of hematologic malignancies. Driven by the motivation to help patients with blood disorders that have largely eluded other targeted approaches, Syros is advancing our clinical-stage drug candidate, tamibarotene, across two genomically defined patient populations in higher-risk myelodysplastic syndrome (HR-MDS) and acute myeloid leukemia (AML).

HEMATOLOGY FOCUSED LATE-STAGE CLINICAL PIPELINE

Program	Indication	Early Clinical	Mid-clinical	Pivotal	Commercial Rights
Tamibarotene (oral RAR α agonist)	(Newly diagnosed HR-MDS (w/aza)	Phase 3 SELECT-MDS-1			 Americas, Europe, Australia and Israel
	(Newly diagnosed unfit AML (w/ven+aza)	Phase 2 SELECT-AML-1			

MARKET OPPORTUNITY

MYELODYSPLASTIC SYNDROME (MDS)

~18,500 Newly diagnosed HR-MDS patients in the US and EU annually ¹

ACUTE MYELOID LEUKEMIA (AML)

~25,000 Newly diagnosed Unfit AML patients in the US and EU annually ¹

**PROJECTED MDS
GLOBAL MARKET BY 2028:**

~\$4.7B²

**PROJECTED AML
GLOBAL MARKET BY 2028:**

~\$7.5B³

MULTIPLE VALUE-DRIVING MILESTONES

Tamibarotene in HR-MDS	Last patient enrolled for the primary endpoint analysis from SELECT-MDS-1 Phase 3 trial	✓
	Pivotal data for complete response (CR) from SELECT-MDS-1 Phase 3 trial	by mid-4Q 24
Tamibarotene in AML	Initial data from randomized SELECT-AML-1 trial	✓
	Additional data from randomized SELECT-AML-1 trial	3Q 24

FAST FACTS

Ticker: NASDAQ: SYRS

Cash and cash equivalents as of 3/31/2024: \$108.3M

Cash Runway: Into Q2 of 2025

Shares outstanding: 39.2M*
*as of 3/31/24, includes 12.5M pre-funded warrants.

Website: www.syros.com

LEADERSHIP TEAM

Conley Chee
Chief Executive Officer

Jason Haas
Chief Financial Officer

Gerald E. Quirk
Chief Legal & Compliance Officer

David A. Roth, MD
Chief Medical Officer

Kristin Stephens
Chief Development Officer

INVESTOR RELATIONS

Karen Hunady
Director of Investor Relations
khunady@syros.com

Hannah Deresiewicz
Stern Investor Relations
hannah.deresiewicz@sternir.com

¹Epidemiology projections from DRG Myelodysplastic Syndromes-Landscape & Forecast-Report 2020 and from DRG Acute Myelogenous Leukemia-Landscape & Forecast-Report 2020 and Syros data on file; ²Evaluate Pharma global market estimate includes all risk groups for MDS; Global market estimate includes all AML (fit and unfit)

OUR PROGRAMS

MYELODYSPLASTIC SYNDROME (MDS)

is a bone marrow disorder in which the bone marrow does not produce enough healthy blood cells. MDS is progressive in nature with a poor prognosis. Approved therapies for higher-risk MDS offer limited efficacy, underscoring the need for better treatment options.

ACUTE MYELOID LEUKEMIA (AML)

is very similar to MDS. AML is a cancer of the blood forming cells in the bone marrow. Approximately 1/3 of patients do not respond to the current standard of care, and nearly all relapse with poor prognosis for survival.

We are developing **TAMIBAROTENE** for the treatment of higher-risk MDS (HR-MDS) and newly diagnosed unfit AML

TAMIBAROTENE (formerly SY-1425) is an oral selective retinoic acid receptor alpha (RARa) agonist that we are developing for genomically defined subsets of patients whose disease is characterized by the overexpression of the *RARA* gene. Approximately 30% of AML patients and 50% of MDS patients have *RARA* overexpression.



of MDS patients are positive for *RARA* overexpression¹



of AML patients are positive for *RARA* overexpression¹

OUR CLINICAL TRIALS

SELECT-MDS-1 (Phase 3)

Investigating tamibarotene in newly diagnosed HR-MDS patients with *RARA* overexpression

- Phase 3, randomized, double-blind, placebo-controlled study
- Evaluating tamibarotene in combination with azacitidine, compared with azacitidine alone
- Primary endpoint for potential approval: Complete response (CR) rate - 190 patients
- Key secondary endpoint of Overall Survival (OS) - approximately 550 patients
- Fast Track designation from the FDA

SELECT-AML-1 (Phase 2)


Investigating tamibarotene in newly diagnosed unfit AML patients with *RARA* overexpression

- Phase 2, randomized study in approximately 80 patients
- Evaluating tamibarotene in combination with venetoclax/azacitidine compared to venetoclax/azacitidine alone
- Primary endpoint for potential approval: Complete response (CR) rate
- Fast Track designation from the FDA

CONSISTENT DATA FROM MULTIPLE TRIALS FOR TAMIBAROTENE

2017


Single-agent tamibarotene in R/R HR-MDS patients²




60% hematologic response, including one bone marrow

2020


Phase 2 data evaluating Tami/Aza in ND unfit AML patients¹



61% CR/CRi



67% CR in low-blast subset



72% Transfusion independence

2023


Phase 2 initial randomized data evaluating Tami/Ven/Aza vs. Ven/Aza in ND unfit AML patients³

Tami/Ven/Aza



100% CR/CRi
78% CR
22% CRi

Ven/Aza



70% CR/CRi
30% CR
40% CRi

FORWARD LOOKING STATEMENTS

This fact sheet contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 concerning Syros and other matters, such as Syros' clinical development plans, including with respect to tamibarotene, Syros' ability to deliver benefit to patients and value to stockholders, the timing and impact of upcoming clinical data readouts, and the sufficiency of Syros' capital resources to fund its operating expenses and capital expenditure requirements into Q2 of 2025. These statements may discuss goals, intentions and expectations as to future plans, trends, events, results of operations or financial condition, or otherwise, based on management's current beliefs, as well as assumptions made by, and information currently available to, management. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as "may," "will," "should," "would," "expect," "anticipate," "plan," "likely," "believe," "estimate," "project," "intend," and other similar expressions. Statements that are not historical facts are forward-looking statements. Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties and are not guarantees of future performance. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors, including, without limitation, Syros' ability to: advance the development of its programs, including tamibarotene, under the timelines it projects in current and future clinical trials; demonstrate in any current and future clinical trials the requisite safety, efficacy and combinability of its drug candidates; sustain the response rates and durability of response seen to date with its drug candidates; successfully develop a companion diagnostic test to identify patients with the *RARA* biomarker; obtain and maintain patent protection for its drug candidates and the freedom to operate under third party intellectual property; obtain and maintain necessary regulatory approvals; identify, enter into and maintain collaboration agreements with third parties; manage competition; manage expenses; raise the substantial additional capital needed to achieve its business objectives; attract and retain qualified personnel; and successfully execute on its business strategies. The foregoing review of important factors that could cause actual events to differ from expectations should not be construed as exhaustive and should be read in conjunction with statements that are included herein and elsewhere, including the risk factors included in Syros' public filings with the U.S. Securities and Exchange Commission. Except as required by applicable law, Syros undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise.

¹de Botton S., et. al. Blood Advances 2022; ²Data presented at ASH 2017, and Syros Data on File; ³Data presented by Syros 06Dec2023